Impact of Alcohol Consumption on the Outcome of Ischemic Stroke and Thrombolysis: Role of the Hepatic Clearance of Tissue-Type Plasminogen Activator

Stroke

Volumn 46, Issue 6, 2015, Pages 1641-1650

  Lemarchand, Eloïse ^a   Gauberti, Maxime ^a   Martinez De Lizarrondo, Sara ^a   Villain, Hélène ^a   Repessé, Yohann ^a,b   Montagne, Axel ^a   Vivien, Denis ^a   Ali, Carine ^a   Rubio, Marina ^a,b  

^a UNIVERSITÉ DE CAEN   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

ethanol; fibrinolysis; intravital microscopy

Indexed keywords

DRINKING WATER; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CONTROLLED STUDY; HEPATIC CLEARANCE; IMMUNOHISTOLOGY; IN VITRO STUDY; MICROSCOPY; NONHUMAN; OUTCOME ASSESSMENT; PHOTON; PRIORITY JOURNAL; THROMBOEMBOLISM; ADVERSE EFFECTS; ANIMAL; DISEASE MODEL; DRINKING BEHAVIOR; FIBRINOLYTIC THERAPY; LIVER; METABOLISM; MOUSE; PATHOLOGY; STROKE;

ALCOHOL DRINKING; ANIMALS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; LIVER; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MICE; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84942859189     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.007143     Document Type: Article

References (44)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, et al; SITS investigators. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol. 2010;9:866-874. doi: 10.1016/S1474-4422(10)70165-4.
3. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci. 2009;32:48-55. doi: 10.1016/j.tins.2008.09.006.
4. Kim EY, Heo JH, Lee SK, Kim DJ, Suh SH, Kim J, et al. Prediction of thrombolytic efficacy in acute ischemic stroke using thin-section noncontrast CT. Neurology. 2006;67:1846-1848. doi: 10.1212/01. wnl.0000244492.99737.a8.
5. Bhatia R, Hill MD, Shobha N, Menon B, Bal S, Kochar P, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010;41:2254-2258. doi: 10.1161/STROKEAHA.110.592535.
6. Riedel CH, Zimmermann P, Jensen-Kondering U, Stingele R, Deuschl G, Jansen O. The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke. 2011;42:1775-1777. doi: 10.1161/STROKEAHA.110.609693.
7. Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ. 2011;342:d636.
8. Hansagi H, Romelsjö A, Gerhardsson de Verdier M, Andreásson S, Leifman A. Alcohol consumption and stroke mortality. 20-year followup of 15,077 men and women. Stroke. 1995;26:1768-1773.
9. Hart CL, Smith GD, Hole DJ, Hawthorne VM. Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: results from a prospective cohort study of scottish men with 21 years of follow up. BMJ. 1999;318:1725-1729.
10. Ducroquet A, Leys D, Al Saabi A, Richard F, Cordonnier C, Girot M, et al. Influence of chronic ethanol consumption on the neurological severity in patients with acute cerebral ischemia. Stroke. 2013;44:2324-2326. doi: 10.1161/STROKEAHA.113.001355.
11. Rubio M, Villain H, Docagne F, Roussel BD, Ramos JA, Vivien D, et al. Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults. PLoS One. 2011;6:e23690. doi: 10.1371/journal. pone.0023690.
12. Mandybur TI, Mendenhall CL. The effects of chronic alcoholism on development of ischemic cerebral infarcts following unilateral carotid artery ligation in gerbils. Alcohol Clin Exp Res. 1983;7:357-361.
13. Zhao H, Mayhan WG, Arrick DM, Xiong W, Sun H. Dose-related influence of chronic alcohol consumption on cerebral ischemia/reperfusion injury. Alcohol Clin Exp Res. 2011;35:1265-1269. doi:10.1111/j.1530-0277.2011.01461.x.
14. Favalli L, Rozza A, Frattini P, Masoero E, Scelsi R, Pascale A, et al. Ischemia-induced glutamate release in rat frontoparietal cortex after chronic alcohol and withdrawal. Neurosci Lett. 2002;326:183-186.
15. Takada T, Yasaka M, Minematsu K, Naritomi H, Yamaguchi T. Predictors of clinical outcome in patients receiving local intra-arterial thrombolysis without subsequent symptomatic intracranial hemorrhage against acute middle cerebral artery occlusion. AJNR Am J Neuroradiol. 2004;25:1796-1801.
16. Bu G, Warshawsky I, Schwartz AL. Cellular receptors for the plasminogen activators. Blood. 1994;83:3427-3436.
17. Strickland DK, Medved L. Low-density lipoprotein receptor-related protein (LRP)-mediated clearance of activated blood coagulation co-factors and proteases: clearance mechanism or regulation J Thromb Haemost. 2006;4:1484-1486. doi: 10.1111/j.1538-7836.2006.01987.x.
18. Gauberti M, Montagne A, Marcos-Contreras OA, Le Béhot A, Maubert E, Vivien D. Ultra-sensitive molecular MRI of vascular cell adhesion molecule-1 reveals a dynamic inflammatory penumbra after strokes. Stroke. 2013;44:1988-1996. doi: 10.1161/STROKEAHA.111.000544.
19. Molina CA, Montaner J, Abilleira S, Ibarra B, Romero F, Arenillas JF, et al. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke. 2001;32:1079-1084.
20. Orset C, Macrez R, Young AR, Panthou D, Angles-Cano E, Maubert E, et al. Mouse model of in situ thromboembolic stroke and reperfusion. Stroke. 2007;38:2771-2778. doi: 10.1161/STROKEAHA.107.487520.
21. Macrez R, Obiang P, Gauberti M, Roussel B, Baron A, Parcq J, et al. Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-D-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis. Stroke. 2011;42:2315-2322. doi: 10.1161/STROKEAHA.110.606293.
22. Striggow F, Riek M, Breder J, Henrich-Noack P, Reymann KG, Reiser G. The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations. Proc Natl Acad Sci USA. 2000;97:2264-2269. doi: 10.1073/pnas.040552897.
23. Xue M, Del Bigio MR. Acute tissue damage after injections of thrombin and plasmin into rat striatum. Stroke. 2001;32:2164-2169.
24. Gauberti M, Martinez de Lizarrondo S, Orset C, Vivien D. Lack of secondary microthrombosis after thrombin-induced stroke in mice and non-human primates. J Thromb Haemost. 2014;12:409-414. doi: 10.1111/jth.12487.
25. Overgaard K, Sereghy T, Pedersen H, Boysen G. Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model. Neuroreport. 1992;3:925-928.
26. Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissuetype plasminogen activator administration in a rat model of embolic stroke. Circulation. 2002;106:740-745.
27. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703. doi: 10.1016/S0140-6736(10)60491-6.
28. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929-1935. doi:10.1016/S0140-6736(14)60584-5.
29. Kuiper J, Otter M, Rijken DC, van Berkel TJ. Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells. J Biol Chem. 1988;263:18220-18224.
30. DeSancho, M and Pastores, S. The liver and coagulation. In: Rodes J, Benhamou JP, Blei AT, Reichen J, Rizzeto M, eds. Textbook of Hepatology: From Basic Science to Clinical Practice. 3rd ed. Oxford: Blackwell Publishing Ltd; 2007:255-264.
31. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost. 2004;91:267-275. doi: 10.1160/TH03-05-0310.
32. Bertola A, Mathews S, Ki SH, Wang H, Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc. 2013;8:627-637. doi: 10.1038/nprot.2013.032.
33. Manzo-Avalos S, Saavedra-Molina A. Cellular and mitochondrial effects of alcohol consumption. Int J Environ Res Public Health. 2010;7:4281-4304. doi: 10.3390/ijerph7124281.
34. Cook RT, Schlueter AJ, Coleman RA, Tygrett L, Ballas ZK, Jerrells TR, et al. Thymocytes, pre-B cells, and organ changes in a mouse model of chronic ethanol ingestion-absence of subset-specific glucocorticoidinduced immune cell loss. Alcohol Clin Exp Res. 2007;31:1746-1758. doi: 10.1111/j.1530-0277.2007.00478.x.
35. Grenett HE, Aikens ML, Tabengwa EM, Davis GC, Booyse FM. Ethanol downregulates transcription of the PAI-1 gene in cultured human endothelial cells. Thromb Res. 2000;97:247-255.
36. Grenett HE, Wolkowicz PE, Benza RL, Tresnak JK, Wheeler And CG, Booyse FM. Identification of a 251-bp fragment of the PAI-1 gene promoter that mediates the ethanol-induced suppression of PAI-1 expression. Alcohol Clin Exp Res. 2001;25:629-636.
37. Tanswell P, Seifried E, Su PC, Feuerer W, Rijken DC. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther. 1989;46:155-162.
38. Nagaoka MR, Kouyoumdjian M, Borges DR. Hepatic clearance of tissue-type plasminogen activator and plasma kallikrein in experimental liver fibrosis. Liver Int. 2003;23:476-483.
39. Pawlak R, Melchor JP, Matys T, Skrzypiec AE, Strickland S. Ethanolwithdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci USA. 2005;102:443-448.
40. Alvarez V, Rossetti AO, Papavasileiou V, Michel P. Acute seizures in acute ischemic stroke: does thrombolysis have a role to play J Neurol. 2013;260:55-61. doi: 10.1007/s00415-012-6583-6.
41. Kassner A, Roberts TP, Moran B, Silver FL, Mikulis DJ. Recombinant tissue plasminogen activator increases blood-brain barrier disruption in acute ischemic stroke: an MR imaging permeability study. AJNR Am J Neuroradiol. 2009;30:1864-1869. doi: 10.3174/ajnr.A1774.
42. Gaberel T, Montagne A, Lesept F, Gauberti M, Lemarchand E, Orset C, et al. Urokinase versus Alteplase for intraventricular hemorrhage fibrinolysis. Neuropharmacology. 2014;85:158-165. doi: 10.1016/j. neuropharm.2014.05.001.
43. Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg. 2007;24:250-258. doi: 10.1159/000103655.
44. De Gasperi A, Corti A, Mazza E, Prosperi M, Amici O, Bettinelli L. Acute liver failure: managing coagulopathy and the bleeding diathesis. Transplant Proc. 2009;41:1256-1259. doi: 10.1016/j.transproceed. 2009.03.007.